65 / 74 · 0:53 · Original AXON film
Tesamorelin
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
US LABEL | HIV-associated lipodystrophy
Tesamorelin is a growth hormone-releasing factor analog. Its US prescribing information addresses a specific clinical problem: excess abdominal fat in adults with HIV-associated lipodystrophy. [1]
Studied endpoint: visceral fat
The clinical studies evaluated visceral fat in that population. This evidence should not be converted into a general promise of weight loss or rejuvenation. [1]
Label limits remain part of the evidence
The label explicitly says tesamorelin is not indicated for weight-loss management. It also states that long-term cardiovascular safety has not been established. [1]
Risks belong in the summary
Important risks include glucose intolerance, elevated IGF-1 and fluid retention. Product identity, patient population and outcome must stay attached when summarizing the research. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- FDA (March 2025): EGRIFTA WR (tesamorelin) prescribing information →Specific indication, clinical evidence, weight-management limitation, unestablished long-term cardiovascular safety and labelled risks.
